Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis
Recent cohort studies demonstrated better overall survival (OS) or breast cancer-specific survival (BCS) for breast-conserving therapy (BCT) followed by radiation (RT) compared to mastectomy alone (MT). This is the first observational study in which adjustments for a comprehensive set of prognostic factors, adjuvant therapies, mode of detection, and comorbidities were possible to investigate OS, BCS, as well as recurrence risk of patients undergoing BCT + RT, MT + RT, or MT.
Women aged 50–74 years at diagnosis of early-stage invasive breast cancer (I–IIIa) between 2001 and 2005 at the German population-based case–control study (MARIE study) were recruited and followed prospectively as a case cohort until 2015. Kaplan–Meier estimates and stepwise adjusted multivariable Cox models were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI).
The 2762 patients included were followed up for a median of 11.9 years (95% CI 11.8–12.0). 74.2% of patients underwent BCT + RT; 10.3% MT + RT and 15.6% MT alone. Compared to patients treated with MT alone, patients treated with BCT + RT showed non-statistically significant improved OS (HR 0.79, 95% CI 0.61–1.02), BCS (HR 0.79, 95% CI 0.55–1.12), and no difference in recurrence risks (HR 1.01, 95% CI 0.74–1.37). For patients treated with MT + RT, there were no differences in OS (HR 1.06, 95% CI 0.75–1.50), BCS (HR 1.17, 95% CI 0.75–1.82), or recurrence risk (HR 1.33, 95% CI 0.89–1.97).
Among patients with early-stage breast cancer, clinical outcomes more than 10 years after diagnosis did not differ between the primary treatment options BCT + RT, MT + RT versus MT alone after full adjustment.
KeywordsEarly-stage breast cancer Mastectomy Breast-conserving therapy Survival Prognosis
Breast cancer-specific survival
- ER/PR receptor
International classification of diseases, 10th revision
Randomized clinical trials
We are grateful to all MARIE study participants. We also thank U. Eilber, S. Behrens, J. Mertin, J. Roczen, and T. Olchers for most valuable technical assistance and data management. The MARIE, MARIEplus, and MARIEplus2 study were funded by the Deutsche Krebshilfe e.V. (#70-2892-BR I, #108253 and #108419, #70110826 and #70112562).
Compliance with ethical standards
Conflicts of interest
The authors declare no conflict of interest.
- 1.Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822–828CrossRefPubMedGoogle Scholar
- 2.Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, Mouridsen HT (2008) Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 47:672–681CrossRefPubMedGoogle Scholar
- 3.Litiere S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van LE, Baaijens MH, Bogaerts J, Bartelink H (2012) Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial 324 324 35244. Lancet Oncol 13:412–419CrossRefPubMedGoogle Scholar
- 5.Wilkinson JB, Vicini FA, Shah C, Shaitelman S, Jawad MS, Ye H, Kestin LL, Goldstein NS, Martinez AA, Benitez P, Chen PY (2012) Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ. Ann Surg Oncol 19:3785–3791CrossRefPubMedGoogle Scholar
- 7.van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, van der Schueren E, Sylvester R, Winter J, van Zijl K (1992) Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr 11:15–18Google Scholar
- 8.AWMF-Register-Nummer: 032-045OL K 3 (2012) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Cited 2016 Mar 24; http://www.awmf.org/uploads/tx_szleitlinien/032-045OL_k_S3__Brustkrebs_Mammakarzinom_Diagnostik_Therapie_Nachsorge_2012-07.pdf
- 9.Heil J, Rauch G, Szabo AZ, Garcia-Etienne CA, Golatta M, Domschke C, Badiian M, Kern P, Schuetz F, Wallwiener M, Sohn C, Fries H et al (2013) Breast cancer mastectomy trends between 2006 and 2010: association with magnetic resonance imaging, immediate breast reconstruction, and hospital volume. Ann Surg Oncol 20:3839–3846CrossRefPubMedGoogle Scholar
- 11.Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V et al (2012) Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer 48:1947–1956CrossRefPubMedGoogle Scholar
- 12.Katipamula R, Degnim AC, Hoskin T, Boughey JC, Loprinzi C, Grant CS, Brandt KR, Pruthi S, Chute CG, Olson JE, Couch FJ, Ingle JN et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA, Investigation O, Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA, Investigation O (2014) Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 37232:1–8Google Scholar
- 14.Gomez SL, Lichtensztajn D, Kurian AW, Telli ML, Chang ET, Keegan THM, Glaser SL, Clarke CA (2010) Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol 28:e155–e157; author reply e158Google Scholar
- 19.Grover S, Nurkic S, Diener-West M, Showalter SL (2016) Survival after breast-conserving surgery with whole breast or partial breast irradiation in women with early stage breast cancer: a SEER data-base analysis. Breast J. http://doi.wiley.com/10.1111/tbj.12729
- 20.Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygård JF (2015) Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: a registry-based follow-up study of Norwegian women primary operated between 1998 and 2008. Ann Surg Oncol 22:3836–3845CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123:933–941CrossRefPubMedGoogle Scholar
- 29.van der Sangen MJC, van Wiel FMM, Poortmans PMP, Tjan-Heijnen VCG, Nieuwenhuijzen GAP, Roumen RMH, Ernst MF, Tutein Nolthenius-Puylaert MCBJE, Voogd AC (2011) Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤ 40 years. Breast Cancer Res Treat 127:207–215CrossRefPubMedGoogle Scholar
- 30.Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW (1998) Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40:859–867CrossRefPubMedGoogle Scholar
- 32.de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42:351–356CrossRefPubMedGoogle Scholar
- 33.Jones HA, Antonini N, Hart AAM, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van Den Bogaert WF, Fourquet A et al (2009) Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 27:4939–4947CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Slanger T, Mutschelknauss E, Kropp S, Braendle W, Flesch-Janys D, Chang-Claude J (2007) Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy. Ann Epidemiol 17:993–998CrossRefPubMedGoogle Scholar
- 37.Tuttle TM, Habermann EB (2011) Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Breast Dis 22:289–290Google Scholar
- 41.van Nes JGH, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJH, Hasenburg A, Rea DW, Vannetzel J-M, Dirix L, Hozumi Y, Kerin MJ et al (2010) Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg 97:671–679CrossRefPubMedGoogle Scholar